Critical appraisal of the Portuguese clinical guideline 28/2011  by Sousa-Veloso, T.
RESEARCH  LETTERS  181
of  age,  with  elective  indication  in  61%.  Elective  ventilation
was  started  at  hospital  setting  in  42  patients  and  out-
patient  setting  in  15  patients  since  2012.  Patients  under
domiciliary  ventilation  also  were  provided  with  respiratory
therapeutic  equipment  at  home:  in-exsufﬂater,  oximeter,
respiratory  secretions  suction  device,  oxygen  therapy,  neb-
ulizer  and  glossopharyngeal  breathing.  During  follow-up
(3.1  ±  2.8  years,  maximum  12.5  years),  55.9%  had  no  hospi-
talizations  and  41.9%  had  less  than  two  hospital  stays/year.
No  major  complications  related  with  ventilation  requiring
its  withdraw  were  described.
The  exponential  ventilation  use  in  paediatric  chronic
patients  in  our  IDVC  follows  the  international  trend  during
the  last  decade  in  developed  countries,1,2 mainly  by  an
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iincrease  of  NIV.  We  report  a  higher  percentage  of  patients
under  domiciliary  NIV  than  most  centers.  Noninvasive
ventilation  advantages  include  lower  infection  risk,  more
independence  and  less  vocal  commitment.3
There  was  a  reduced  need  of  hospital  admission  for  ven-
tilation  adaptation,  which  can  be  related  to  a  better  use  of
resources  available  in  the  hospital  and  community  and  the
efﬁcient  home  monitoring  provided  by  the  IDVC  program.
Ambulatory  ventilation  adaptation  beneﬁts  have  not  been
studied  in  children,  but  studies  in  adults  have  proven  sim-
ilar  clinical  efﬁcacy  while  reducing  the  economic  costs  by
50--70%.4,5
In  most  of  our  cases  there  was  a  low  number  of  hospital
admissions  (0.5  hospital  admission/patient/year)  in  spite  of
patients’  disease  complexity,  as  has  been  reported  in  other
centres  with  paediatric  multidisciplinary  ventilation  clin-
ics  (0.17--1.6  hospital  admissions/patient/year  in  different
demographic  and  clinic  groups  of  paediatric  patients).6,7
Close  cooperation  between  patient,  his  family  and  a
specialized  group  of  health  care  professionals  can  improve
clinical  outcomes.  Domiciliary  care  and  monitoring  in  con-
tinuum  with  hospital  multidisciplinar  assessments  might
improve  respiratory  care  for  chronic  paediatric  patients
needing  domiciliary  ventilation.  Outpatient  clinic  models,
like  the  IDVC  described,  can  be  integration  tools  between
home  and  hospital  care.
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‘‘It  is  not  recommended  the  regular  prescription  of
mucolytics  nor  antitussive  agents.’’
(DGS  Guideline  28/2011  -  COPD,  p.  5).
This  sentence  addresses  two  very  different  therapeutic
categories.  We  agree  only  with  the  antitussive  agents  part.
According  to  the  2015  update  of  GOLD  guidelines,1
which  address  chronic  obstructive  pulmonary  disease
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COPD),  the  use  of  mucolytics,  such  as  N-acetylcysteine  or
arbocysteine,  can  have  a  positive  effect  on  the  reduction
f  the  number  of  exacerbations.  The  most  recent  Cochrane2
eview  on  the  issue  included  many  non-identical  stud-
es  (a  very  high  heterogeneity  index,  I2 =  87%),  which
akes  it  particularly  difﬁcult  to  identify  statistically  sig-
iﬁcant  difference  between  groups.  Despite  this  fact,  the
eneﬁt  reported  from  the  use  of  mucolytics  was  signif-
cant  as  far  as  exacerbation  reduction  was  concerned
OR  1.84;  CI95% 1.63--2.07),  which  can  also  be  trans-
ated  into  a  number  needing  to  be  treated  of  7 (one
hould  treat  7  patients  for  at  least  10  months  in  order
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to  achieve  a  reduction  of  1  exacerbation  episode),  as
well  as  on  the  statistically  signiﬁcant  lowering  of  the
number  of  sick  days  (on  average,  a  decrease  of  0.48  days,
CI95% −0.65  to  −0.30).
Following  what  has  been  said,  we  think  that  the  sen-
tence  ‘‘It  is  not  recommended  the  regular  prescription  of
mucolytics  nor  antitussive  agents.’’  does  not  reﬂect  the  real
potential  beneﬁt  underlying  the  mucolytic  drugs  in  COPD
patients,  which  has  the  additional  advantage  of  low  risk  of
adverse  events.
Therefore,  we  propose  that  the  phrase  quoted  be
replaced  by  sentences  such  as  the  two  that  follows:
1)  ‘‘The  real  impact  of  a  regular  prescription  of  mucolytic
agents  is  still  not  thoroughly  understood.  It  should  be
emphasized  that  among  COPD  patients  of  moderate  or
high  severity,  the  regular  use  of  mucolytics  (such  as  N-
acetylcysteine  of  carbocystein)  can  have  a  beneﬁcial
effect  on  the  decrease  of  the  number  of  exacerbation
episodes,* as  well  as  on  the  reduction  of  the  number  of
sick  leave  days.†’’
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2)  ‘‘We  do  not  recommend  the  regular  prescription  of  anti-
tussive  agents,  as  they  have  the  potential  for  inhibiting
the  protective  airway  cough  reﬂex.’’
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